Combined Atherosclerotic Lesions of Cerebral and Coronary Blood Vessels: Risk Factors


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Data is presented specifying the extent of influence of traditional and novel (C-reactive protein (CRP), fibrinogen, intima-media complex (IMC)) risk-factors of atherosclerotic lesions upon cerebral blood vessels in case of isolated variant vs. combined lesions of coronary and cerebral blood vessels. The role of CRP and fibrinogen as atherosclerotic process development markers is discussed. The most significant risk factors of combined and isolated atherosclerotic lesions of coronary and cerebral blood vessels are discussed important for understanding of this pathology ethiology and pathogenesis. Pathogenetic interrelation of cerebral and cardiac pathology is specified manifesting itself by mutual aggravation in case of atherosclerotic process. Pathophysiologic mechanisms of cerebral and coronary blood vessels’ atherosclerotic lesions are common, hence the risk factors are also analogous, however their import is not identical in case of isolated and combined variants and this feature should be taken into account while working out the approach to this ailment treatment and prophylaxis. Atherosclerotic lesions of arteries from various vascular basins alongside with common pathophysiologic mechanisms also possess a score of peculiarities that predetermine different approaches to their treatment and prophylaxis. Separate risk factors determine predominant localization of pathologic process in certain vascular basins thus identification of isolated and combined coronary and cerebral principal blood vessels atherosclerotic lesions’ risk factors is a subject of profound studies. Thus working out new approaches to cerebrovascular ailments risk prognosis on the basis of cardiovascular ailments risk factors as well as existing prophylactic measures monitoring is actual for contemporary medicine.

Full Text

Restricted Access

About the authors

Robert Vladimirovich Bilyutin-Aslanyan

Saint Petersburg State Pediatric Medical University

Email: bio-wolf87@mail.ru
MD, PhD student at Dept. Pathophysiology & Immunopathology

Andrei Glebovich Vasiliev

Saint Petersburg State Pediatric Medical University

Email: avas7@mail.ru
MD, PhD, Dr Med Sci, Professor, Head Dept. Pathophysiology & Immunopathology

Pavel Vasil’yevich Rodichkin

Herzen State Pedagogical University of Russia

Email: rodichkin.pavel@gmail.com
MD, PhD, Dr Med Sci, Professor, Professor Dept. Theory and method of Physical Training

Aleksandr Petrovich Trashkov

Saint Petersburg State Pediatric Medical University

Email: trashkov@gmail.com
MD, PhD, Assoc. Professor., Dept. Pathophysiology & Immunopathology

Nikolay Valentinovich Khaytsev

Saint Petersburg State Pediatric Medical University

Email: nvh195725@gmail.com
MD, PhD, Dr Biol Sci, Professor, Dept. Pathophysiology & Immunopathology

References

  1. Барабаш О. Л., Зыков М. В., Кашталап В. В. Распространенность и клиническая значимость мультифокального атеросклероза у пациентов с ишемической болезнью сердца. Кардиология. 2011; 8: 66-71.
  2. Васильев А. Г., Комяков Б. К., Тагиров Н. С., Мусаев С. А. Чрескожная нефролитотрипсия в лечении коралловидного нефролитиаза. Профилактическая и клиническая медицина. 2009; 4: 183-6.
  3. Васильев А. Г., Петрищев Н. Н. Патология, учебное пособие. М.: Академия. 2012; 528.
  4. Васильев А. Г., Хайцев Н. В., Трашков А. П. Практикум по патофизиологии. Учебное пособие под ред. профессоров А. Г. Васильева и Н. В. Хайцева. СПб.: Фолиант. 2014; 344.
  5. Васильев А. Г., Чурилов Л. П. Иммунология и иммунопатология. Руководство по иммунологии и иммунопатологии. СПб.: Сотис. 2006; 180.
  6. Васильев Г. А., Хайцев Н. В. Онтогенетические особенности ответных реакций организма на хроническое воздействие химических веществ. Гигиена и санитария. 1991; 5: 65-7.
  7. Гайсенок О. В., Деев А. Д., Мазаев В. П. и др. О роли известных факторов риска как предикторах выявления атеросклеротического поражения коронарных и сонных артерий. Профилактическая медицина. 2012; 15(2): 30.
  8. Корнева В. А. Мультифокальный атеросклероз: клинико-патогенетические синдромы. Регионарное кровообращение и микроциркуляция. 2006; 6 (4): 45-53.
  9. Кузнецов А. Н. Мультифокальный атеросклероз. Современные принципы лечения мультифокального атеросклероза. Вестник Национального медико-хирургич. центра имени Н. И. Пирогова. 2008; 3 (2): 78-83.
  10. Лелюк В. Г., Лелюк С. Э. Ультразвуковая ангиография. М.: Медицина. 2003; 324.
  11. Лутай М. И. Мультифокальный атеросклероз: польза статинов. Діабет і серце; 2011: 6: 152. Статины в лечении пациентов высокого риска: www.healt.ua.com.
  12. Мировой отчет по неинфекционным заболеваниям. Женева: ВОЗ. 2010; 233.
  13. Национальные клинические рекомендации. Сборник под. ред. Р. Г. Оганова, 2-е издание. М.: Силицея-Полиграф. 2009; 528.
  14. Суслина З. А., Варакин Ю. Я. Эпидемиологические аспекты изучения инсульта. Время подводить итоги. Анналы клинической и экспериментальной неврологии. 2007; 1 (2): 22-8.
  15. Тагиров Н. С., Назаров Т. Х., Васильев А. Г., Лихтшангоф А. З., Лазаренко И. Б., Маджидов С. А., Ахмедов М. А. Опыт применения чрескожной нефролитотрипсии и контактной уретеролитотрипсии в комплексном лечении мочекаменной болезни. Профилактическая и клиническая медицина. 2012; 4: 30-3.
  16. Цыган Н. В., Одинак М. М., Пелешок А. С., Марченко С. П., Наумов А. Б., Трашков А. П., Васильев А. Г., Хубулава Г. Г., Леванович В. В. Нейропротекция при реконструктивных операциях на дуге аорты. Вестник Российской военно-медицинской академии. 2012; 2: 119-27.
  17. Чазова И. Е., Ратова Л. Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика. 2007; 183.
  18. Шляхто Е. В. Кардиология для практического врача. Гипертоническая болезнь. СПб.: ГЭОТАР. 2010; 780.
  19. Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J. Neurol Neurosurg Psychiatry. 2011; 82: 986-92.
  20. Amarenco P., Benavente O., Goldstein L. B. et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009; 40 (4): 1405-9.
  21. Azarpazhooh M. R., Nicol M. B., Donnan G. A. et al. Patterns of stroke recurrence according to subtype of first stroke event: the North East Melbourne Stroke Incidence Study (NEMESIS). Int. J. Stroke. 2008; 3: 158-64.
  22. Blankenberg S., Yusuf S. The inflammatory hypothesis: any progress in risk stratificationand therapeutic targets? Circulation. 2006; 114 (15): 1557-60.
  23. Brunzell J. D. Clinical practice. Hypertriglyceridemia N. Engl. J. Med. 2007; 357 (10): 1009-17.
  24. Di Tullio M. R., Homma S., Jin Z. et al. Aortic Atherosclerosis, Hypercoagulability, and Stroke The APRIS (Aortic Plaque and Risk of Ischemic Stroke). J. Am. Coll. Cardiol. 2008; 52 (10): 855-61.
  25. Elkind M. S. Inflammation, atherosclerosis, and stroke. Neurologist. 2006; 12 (3): 140-8.
  26. Flegar-Mestrić Z., Vrhovski-Hebrang D., Preden-Kereković V. et al. C-reactive protein level in severe stenosis of cerebral arteries. Journal Cerebrovasc Dis. 2007; 23 (5-6): 430-4.
  27. Fornoni A., Raij I. Metabolic syndrome and endothelian dysfunction. Current Atherosclerosis Reports. 2005; 7: 88-95.
  28. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization. 2011.
  29. Hackam D. G. Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke. A Quantitative Modeling Study. Stroke. 2007; 38: 1881-5.
  30. Haslam D. W. Obesity. Lancet. 2005; 366: 1197-209.
  31. Kabłak-Ziembicka A., Przewłocki T., Stępień Е. et al. Relationship between carotid intima-media thickness, cytokines, atherosclerosis extent and a two-year cardiovascular risk in patients with arteriosclerosis. Department of Cardiac and Vascular Diseases, Jagiellonian University, School of Medicine, The John Paul II Hospital, Krakow, Poland Kardiologia Polska. 2011; 69 (10): 1024-31.
  32. Kovacika M., Madaraszb S., Krala M. et al. Risk factors associated with ischemic heart disease occurence in acute ischemic stroke patients. Biomedical papers no 2Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157 (2): 168-71.
  33. Libby P., Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med. 2002; 8 (11): 1257-62.
  34. Lim P., Moutereau S., Simon T. et al. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]). Am. J. Cardiol. 2013; 111: 31-7.
  35. López-Cuenca A., Manzano-Fernández S., Lip G. Y. et al. Interleucina 6 y proteína C reactiva ultrasensible para la predicción de la evolución clínica en síndromes coronarios agudos sin elevación del segmento ST. Rev. Esp. Cardiol. 2013; 66: 185-92.
  36. Mathers C. D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006. 3 (11): 442.
  37. Mathiesen E. B., Johnsen S. H., Wilsgaard T. et al. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke: a 10-year follow-up of 6584 men and women: the Tromson study. Stroke. 2011; 42 (4): 972-8.
  38. Mente A., Yusuf S., Islam S. et al. Metabolic Syndrome and Risk of Acute Myocardial Infarction: A Case-Control Study of 26,903 Subjects From 52 Countries. Journal of the American College of Cardiology. 2010; 55: 2390-8.
  39. Mora S., Rifai N., Buring J. E. et al. Additive value of immunoassaymeasured fibrinogenand highsensitivityCreactive protein levels for predicting incident cardiovascular events. Circulation. 2006; 114 (5): 381-7.
  40. Mvundura M., McGruder H., Khoury M. J. et al. Family history as a risk factor for early-onset stroke/transient ischemic attack among adults in the United States. Public Health Genomics. 2010; 13 (1): 13-20.
  41. O'Donnell M. J., Xavier D., Liu L. ey al. INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376 (9735): 112-23.
  42. Papageorgiou N., Tousoulis D., Siasos G. et al. Is Fibrinogen a Marker of Inflammation in Coronary Artery Disease? Hellenic J Cardiol. 2010; 51: 1-9.
  43. Parhami F. et al. Regulation of vascular calcification in atherosclerosis. Z. Kardiol. 2010; 90 (3): 27-30.
  44. Polak J. F., Pencina M. J., O’Leary D. H. et al. Common carotid artery intima-media thickness progression as a predictor of stroke in Multi-Ethnic Study of Atherosclerosis. Stroke. 2011; 42: 3017-21.
  45. Prescott E., Hippe M., Schnohr P. et al. Smoking and risk in the European Union: comparing education and income. Prev. Med. 2005; 40: 756-64.
  46. Ridker P. M. Clinical application of Creactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107 (3): 363-9.
  47. Sacco R. L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006; 37: 577-617.
  48. Shushunov S., Balashov L., Kravtsova A. et al. Determination of acute toxicity of the aqueous extract of potentilla erecta (tormentil) rhizomes in rats and mice. Journal of Medicinal Food. 2009; 12 (5): 1173-6.
  49. Sidney S., Rosamond W. D., Howard V. J. et al. National Forum for Heart Disease and Stroke Prevention. The «heart disease and stroke statistics -2013 update» and the need for a national cardiovascular surveillance system. Circulation. 2013; 127 (1): 21-3.
  50. Spencer F., Lessard D., Emery C. et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007; 167 (14): 1471-5.
  51. Tarantini G., Napodano M., Gasparetto N., et al. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron. Artery. Dis. 2010; 21 (2): 78-86.
  52. Tuttle K. R. Sex differences in risk factors fo r atherosclerosis/K. R. Tuttle, R. A. Short. Am. J. Cardiol. 2008; 87 (6): 1411-4.
  53. Yusuf S., Bernard J. G., Sliwa K. et al. The epidemic of cardiovascular disease in thedeveloping world: global implications. European Heart Journal. 2010; 31: 642-8.
  54. Zhang Li, Yin Ji-Kai, Duan Yun-You et al. Evaluation of carotid artery elasticity changes in patients with type 2 diabetes. Cardiovascular Diabetology. 2014. http:. www.cardiab.com/content/13/1/39.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bilyutin-Aslanyan R.V., Vasiliev A.G., Rodichkin P.V., Trashkov A.P., Khaytsev N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 69634 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies